Varlilumab
| Varlilumab | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 1263383-89-0 |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Varlilumab (also known as CDX-1127) is a monoclonal antibody that targets the CD27 receptor, a member of the tumor necrosis factor receptor superfamily. It is being investigated for its potential use in cancer immunotherapy.
Mechanism of Action[edit]
Varlilumab is designed to modulate the immune system by targeting CD27, a co-stimulatory molecule found on T cells. CD27 plays a crucial role in the activation and survival of T cells, which are essential components of the adaptive immune response. By binding to CD27, varlilumab can enhance T cell activation and proliferation, potentially leading to a more robust anti-tumor immune response.
Clinical Development[edit]
Varlilumab is currently undergoing clinical trials to evaluate its efficacy and safety in treating various types of cancer, including lymphoma, melanoma, and renal cell carcinoma. Early-phase clinical trials have shown promising results, with some patients experiencing tumor shrinkage and prolonged disease stabilization.
Potential Benefits[edit]
The use of varlilumab in cancer therapy is based on its ability to enhance the body's immune response against tumor cells. By activating T cells, varlilumab may help overcome the immunosuppressive environment often found in tumors, allowing the immune system to effectively target and destroy cancer cells.
Side Effects[edit]
As with other immunotherapies, varlilumab can cause immune-related adverse effects. These may include cytokine release syndrome, autoimmune reactions, and other inflammatory responses. Close monitoring and management of these side effects are essential during treatment.
Research and Future Directions[edit]
Ongoing research is focused on optimizing the use of varlilumab in combination with other therapies, such as checkpoint inhibitors and chemotherapy. These combination strategies aim to enhance the overall efficacy of cancer treatment by leveraging multiple mechanisms of action.
Also see[edit]
 | This immunology article is a stub. You can help Wikipedia by adding missing information. |
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
